Compare Stocks: PROK, IOVA, TYRA, and MESO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$4.34 -0.5%	$4.32	$1.76 ▼ $5.64	$1.95B	0.71	16.07 million shs	15.57 million shs
MESO Mesoblast	$14.97 +1.1%	$14.88	$12.66 ▼ $21.50	$1.92B	2.08	297,648 shs	80,709 shs
PROK ProKidney	$1.67 +2.5%	$1.73	$1.45 ▼ $3.48	$492.36M	1.66	1.03 million shs	605,944 shs
TYRA Tyra Biosciences	$25.71 -21.0%	$30.30	$9.96 ▼ $40.65	$1.93B	0.77	552,172 shs	2.74 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	-0.46%	-4.82%	+3.58%	+22.25%	+57.82%
MESO Mesoblast	+1.11%	+5.98%	+4.43%	+1.11%	-4.01%
PROK ProKidney	+2.45%	+8.44%	-16.08%	-11.17%	-47.48%
TYRA Tyra Biosciences	-20.97%	-17.36%	-16.69%	-21.85%	+124.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$4.34 -0.5%	$4.32	$1.76 ▼ $5.64	$1.95B	0.71	16.07 million shs	15.57 million shs
MESO Mesoblast	$14.97 +1.1%	$14.88	$12.66 ▼ $21.50	$1.92B	2.08	297,648 shs	80,709 shs
PROK ProKidney	$1.67 +2.5%	$1.73	$1.45 ▼ $3.48	$492.36M	1.66	1.03 million shs	605,944 shs
TYRA Tyra Biosciences	$25.71 -21.0%	$30.30	$9.96 ▼ $40.65	$1.93B	0.77	552,172 shs	2.74 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	-0.46%	-4.82%	+3.58%	+22.25%	+57.82%
MESO Mesoblast	+1.11%	+5.98%	+4.43%	+1.11%	-4.01%
PROK ProKidney	+2.45%	+8.44%	-16.08%	-11.17%	-47.48%
TYRA Tyra Biosciences	-20.97%	-17.36%	-16.69%	-21.85%	+124.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOVA Iovance Biotherapeutics	2.30	Hold	$8.43	94.21% Upside
MESO Mesoblast	1.00	Sell	N/A	N/A
PROK ProKidney	2.50	Moderate Buy	$12.00	618.56% Upside
TYRA Tyra Biosciences	2.87	Moderate Buy	$46.90	82.42% Upside

Current Analyst Ratings Breakdown

Latest PROK, IOVA, TYRA, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	TYRA Tyra Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
7/17/2026	MESO Mesoblast	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	TYRA Tyra Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	PROK ProKidney	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/25/2026	PROK ProKidney	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/17/2026	TYRA Tyra Biosciences	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$56.00
6/10/2026	TYRA Tyra Biosciences	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $42.00
5/19/2026	TYRA Tyra Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Peer Perform
5/18/2026	PROK ProKidney	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
5/14/2026	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOVA Iovance Biotherapeutics	$263.50M	7.35	N/A	N/A	$1.76 per share	2.47
MESO Mesoblast	$17.20M	113.00	N/A	N/A	$4.67 per share	3.20
PROK ProKidney	$890K	566.79	N/A	N/A	($3.36) per share	-0.50
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOVA Iovance Biotherapeutics	-$390.98M	-$0.95	N/A	N/A	N/A	-123.92%	-50.17%	-38.77%	8/6/2026 (Estimated)
MESO Mesoblast	-$102.14M	-$0.28	N/A	N/A	N/A	N/A	N/A	N/A	9/4/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.53	N/A	N/A	N/A	-8,131.50%	N/A	-21.39%	8/11/2026 (Estimated)
TYRA Tyra Biosciences	-$119.95M	-$2.18	N/A	N/A	N/A	N/A	-48.07%	-44.73%	8/13/2026 (Estimated)

Latest PROK, IOVA, TYRA, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TYRA Tyra Biosciences	-$0.6499	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	PROK ProKidney	-$0.14	N/A	N/A	N/A	$0.19 million	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	N/A	N/A	N/A	$87.83 million	N/A
8/4/2026	Q2 2026	TYRA Tyra Biosciences	-$0.6499	-$0.69	-$0.0401	-$0.69	N/A	N/A
5/15/2026	Q1 2026	PROK ProKidney	-$0.13	-$0.14	-$0.01	-$0.14	$0.10 million	$0.23 million
5/13/2026	Q1 2026	TYRA Tyra Biosciences	-$0.60	-$0.64	-$0.04	-$0.64	N/A	N/A
5/7/2026	Q1 2026	IOVA Iovance Biotherapeutics	-$0.19	-$0.19	N/A	-$0.19	$77.84 million	$71.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOVA Iovance Biotherapeutics	N/A	3.60	3.15
MESO Mesoblast	0.10	1.58	1.41
PROK ProKidney	N/A	9.06	9.06
TYRA Tyra Biosciences	N/A	20.49	20.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOVA Iovance Biotherapeutics	77.03%
MESO Mesoblast	1.43%
PROK ProKidney	51.59%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
IOVA Iovance Biotherapeutics	7.80%
MESO Mesoblast	18.80%
PROK ProKidney	39.83%
TYRA Tyra Biosciences	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOVA Iovance Biotherapeutics	500	446.50 million	411.68 million	Optionable
MESO Mesoblast	80	129.88 million	105.46 million	Optionable
PROK ProKidney	3	302.06 million	181.75 million	Optionable
TYRA Tyra Biosciences	20	59.47 million	52.04 million	Optionable

PROK, IOVA, TYRA, and MESO Headlines

Recent News About These Companies

Tyra Biosciences (TYRA) Expected to Announce Earnings on Thursday

2 hours ago | americanbankingnews.com

Tyra Biosciences (TYRA) Projected to Announce Earnings on Thursday

2 hours ago | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by Analysts

2 hours ago | americanbankingnews.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

2 hours ago | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down Following Weak Earnings

August 5 at 10:19 AM | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 4 at 7:55 PM | marketbeat.com

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

August 4 at 4:05 PM | prnewswire.com

Arkadios Wealth Advisors Makes New $1.82 Million Investment in Tyra Biosciences, Inc. $TYRA

August 3 at 3:04 AM | marketbeat.com

Tyra Biosciences, Inc. $TYRA Stock Position Boosted by Seven Fleet Capital Management LP

August 2, 2026 | marketbeat.com

Janus Henderson Group PLC Acquires 955,147 Shares of Tyra Biosciences, Inc. $TYRA

August 1, 2026 | marketbeat.com

Tyra Biosciences, Inc. $TYRA Shares Sold by Eversept Partners LP

July 28, 2026 | marketbeat.com

Commodore Capital LP Lowers Stake in Tyra Biosciences, Inc. $TYRA

July 27, 2026 | marketbeat.com

Affinity Asset Advisors LLC Makes New $9.86 Million Investment in Tyra Biosciences, Inc. $TYRA

July 25, 2026 | marketbeat.com

Jennison Associates LLC Buys Shares of 632,432 Tyra Biosciences, Inc. $TYRA

July 21, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Up 5% - Here's Why

July 17, 2026 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of "Moderate Buy" by Brokerages

July 12, 2026 | marketbeat.com

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

June 30, 2026 | finance.yahoo.com

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

June 30, 2026 | finance.yahoo.com

Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight

June 23, 2026 | finance.yahoo.com

Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA)

June 20, 2026 | theglobeandmail.com

Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?

June 12, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, IOVA, TYRA, and MESO Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

$4.34 -0.02 (-0.46%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$4.33 -0.01 (-0.25%)

As of 04:25 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Mesoblast NASDAQ:MESO

$14.96 +0.17 (+1.11%)

Closing price 08/5/2026 03:58 PM Eastern

Extended Trading

$14.75 -0.22 (-1.44%)

As of 04:08 AM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

ProKidney NASDAQ:PROK

$1.67 +0.04 (+2.45%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.66 -0.01 (-0.90%)

As of 05:00 AM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tyra Biosciences NASDAQ:TYRA

$25.71 -6.82 (-20.97%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$25.84 +0.13 (+0.50%)

As of 04:09 AM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PROK, IOVA, TYRA, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PROK, IOVA, TYRA, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PROK, IOVA, TYRA, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, IOVA, TYRA, and MESO Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Mesoblast NASDAQ:MESO

ProKidney NASDAQ:PROK

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PROK, IOVA, TYRA, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PROK, IOVA, TYRA, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PROK, IOVA, TYRA, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, IOVA, TYRA, and MESO Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Mesoblast NASDAQ:MESO

ProKidney NASDAQ:PROK

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools